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Background: GSK233705 is an inhaled, long-acting muscarinic antagonist in development 
for the treatment of chronic obstructive pulmonary disease (COPD). This study was performed 
to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than 
salmeterol or tiotropium alone in COPD.
Methods: In an incomplete-block, three-period, crossover design, dually responsive patients 
received three of the following five treatments: GSK233705 20 µg plus salmeterol 50 µg twice-
daily; GSK233705 50 µg plus salmeterol 50 µg twice-daily; salmeterol 50 µg or placebo, each 
twice-daily; and tiotropium 18 µg or placebo once-daily for 7 days. Each treatment period was 
separated by a 14-day washout. The primary efficacy endpoint was morning (trough) forced 
expiratory volume in 1 second (FEV1) on Day 8, following 7 days of treatment. Secondary 
endpoints included pulmonary function, plethysmography, pharmacokinetics of GSK233705 
and salmeterol, adverse events (AEs), electrocardiograms (ECGs), vital signs, and laboratory 
parameters.
Results: A total of 47 patients were randomized. The mean % predicted normal 
postbronchodilator FEV1 was 55% at screening. Compared with placebo (n = 24), the adjusted 
mean change from baseline in trough FEV1 on Day 8 was 215 mL higher with GSK233705 
20 µg + salmeterol (n = 23) and 203 mL higher with GSK233705 50 µg + salmeterol (n = 27), 
whereas with salmeterol (n = 27) and tiotropium (n = 28) the changes were 101 mL and 118 mL 
higher, respectively. The primary efficacy results were supported by the results from the other 
secondary lung function assessments. AEs were reported by similar proportions of patients 
across the treatment groups, with headache the most frequently reported treatment-related AE 
reported by one subject receiving each of GSK233705 20 µg + salmeterol, tiotropium, and 
placebo. No significant differences were seen in vital signs, ECGs, or laboratory parameters 
between the groups.
Conclusion: The addition of GSK233705 to salmeterol in partially reversible COPD patients 
resulted in greater bronchodilation than salmeterol or tiotropium alone and was well tolerated.
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Background
Bronchodilators are the cornerstone of the symptomatic management of COPD and 
current Global initiative for chronic Obstructive Lung Disease guidelines recommend 
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the use of long-acting inhaled bronchodilators in moderate to 
very severe COPD.1,2 The benefits of bronchodilators include 
not only the control of symptoms but also   improvements 
in lung function, hyperinflation, exercise performance, 
exacerbation rate, and health status.
Long-acting inhaled bronchodilators include both 
long-acting β-agonists (LABA), such as formoterol 
or salmeterol, and long-acting muscarinic antagonists 
(LAMA), such as tiotropium bromide. For patients who are 
not sufficiently controlled on maintenance monotherapy, 
combining bronchodilators of different classes, in particular 
a LAMA and a LABA, has been advocated.3 LABA/LAMA 
combinations appear to play an important role in maximizing 
bronchodilation and are well tolerated by the majority of 
patients.4–8
The scientific rationale for combining a LABA and 
  muscarinic antagonist in COPD has been reviewed by 
several authors.9,10 Complementary bronchodilation may 
be obtained either by directly relaxing the smooth muscle 
through stimulation of β2 adrenoceptors or by inhibiting 
the action of acetylcholine at muscarinic receptors with 
muscarinic antagonists, indirectly leading to smooth muscle 
relaxation. Most studies published to date have reported 
the use of a combination of a twice-daily LABA with 
tiotropium4–8,11,12 or twice-daily LABA with short-acting 
muscarinic antagonists.13,14
There are a number of LAMAs in clinical development 
as monotherapies and in fixed combinations with LABAs.9,10 
GlaxoSmithKline (GSK) are also developing novel LAMAs 
and one such compound is twice-daily GSK233705, also 
known as darotropium, a high-affinity pan-active muscarinic 
receptor antagonist (data on file). Phase I and II studies have 
assessed the efficacy, safety, tolerability, pharmacodynam-
ics, and pharmacokinetics of single and repeat doses of 
GSK233705 and shown it to be generally well tolerated and 
an effective bronchodilator.
This pilot study in COPD patients responsive to both 
β-agonists and antimuscarinics was performed to see if the 
addition of GSK233705 to salmeterol would provide greater 
bronchodilation than salmeterol or tiotropium alone.
Methods
Patients and methods
Patients were recruited between October 2006 and May 
2007 at nine centers in Finland, Germany, the Netherlands, 
and the UK. All patients gave written informed consent and 
the protocol was approved by the appropriate institutional 
review boards and conducted in accordance with good 
clinical practice guidelines and the most recent version 
of the Declaration of Helsinki. Patients aged 40–75 years 
with a clinical history of COPD according to the American 
Thoracic Society/European Respiratory Society (ATS/ERS) 
definition,2 a smoking history of $10 pack years, a postbron-
chodilator forced expiratory volume in 1   second (FEV1 ) of 
$40% to #75% of predicted   normal, and a postbronchodila-
tor FEV1/forced vital capacity (FVC) ratio of #70% were 
recruited. In order to recruit the optimum patient population 
for the study, patients also had to demonstrate responsive-
ness/reversibility to both 80 mcg ipratropium bromide and 
400 mcg salbutamol. Responsiveness/Reversibility was 
defined as an increase in FEV1 of $12% and $150 mL 
following inhalation of each bronchodilator administered 
on different occasions. Subjects with very large improve-
ments in FEV1 . 500 mL at testing were excluded as this 
suggested the possibility of an alternative diagnosis.
Patients were excluded from the study if they had 
suffered a COPD exacerbation, had changes in COPD 
medication, or taken antibiotics within 4 weeks prior to 
screening or during the run-in period. Patients were also 
excluded if they had: a current diagnosis of asthma, a his-
tory of asthma, known respiratory disorders (apart from 
COPD), previous lung surgery, or required long-term 
oxygen therapy or pulmonary rehabilitation at screening. 
Patients were excluded if they had significant unstable 
cardiovascular disease.
Study design
This was a multicenter, randomized, partially blinded (active 
versus placebo treatment), placebo-controlled, three-way 
crossover study. Each subject was randomized to receive 
three of a possible five treatments (incomplete block design). 
The five treatments were: GSK233705 20 µg plus salmeterol 
50 µg twice-daily; GSK233705 50 µg plus salmeterol 
50 µg twice-daily; salmeterol 50 µg twice-daily; tiotropium 
  bromide 18 µg once daily; and placebo (GSK study number 
AC2106956; clinical trials.gov NCT00422604).15 After a 
2-week run-in period to establish a stable baseline, subjects 
were randomized to treatment sequences which comprised 
three 7-day treatment periods, each separated by a 14-day 
wash-out period. Two types of inhaler were used for the study 
(Diskus/Accuhaler™ [GlaxoSmithKline, London, UK] for 
GSK233705, salmeterol, and placebo and HandiHaler™ 
[Boehringer Ingelheim, Ingelheim am Rhein, Germany] for 
tiotropium bromide and placebo).
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Concomitant medication
Inhaled salbutamol was provided as a relief medication. 
Other permitted medications included inhaled corticosteroids 
at a dose of up to 1000 µg/day of fluticasone propionate 
or equivalent (provided the dose had remained constant 
for 6 weeks prior to screening and would remain constant 
throughout the study). Patients who were taking LABA/ICS 
combination treatments had the LABA component stopped 
and replaced by the equivalent dose of inhaled corticosteroid 
(ICS) as monotherapy.
Outcome measurements
Lung function was determined by measuring the spirometry 
parameters FEV1 and FVC, and the plethysmography param-
eters airway conductance (sGaw), airways resistance (Raw), 
inspiratory capacity (IC), and residual volume (RV). Both 
trough (measured before the morning dose on Day 2 and Day 
8) and postdose (measured on Day 1 and Day 7) spirometry 
and plethysmography values were recorded with plethysmog-
raphy assessments conducted after spirometry. Serial spirom-
etry was performed on Day 1 and Day 7 of each treatment 
period predose and at 1, 2, 4, 9, 12, and 24 hours following 
the morning dose of study medication. Plethysmography was 
performed predose and at 3, 11, and 25 hours postdose on Day 
1 and Day 7. Subjects also recorded morning peak expiratory 
flow (PEF) prior to the morning dose of study medication 
and relief salbutamol rescue use on daily record cards during 
the run-in, wash-out, and treatment periods.
The primary efficacy endpoint was morning predose 
(trough) FEV1 on Day 8, following 7 days of treatment. 
Secondary lung function endpoints included trough FEV1 
on Day 2; postdose FEV1, FVC, and plethysmography 
measurements on Day 1 and Day 7; trough FVC and trough 
plethysmography measurements on Day 2 and Day 8; and 
morning predose PEF and rescue medication recorded on 
the daily record card.
Safety endpoints included the incidence of adverse 
events (AEs), incidence of COPD exacerbations, vital 
signs (systolic and diastolic blood pressure and heart 
rate), and clinical laboratory tests (hematology, chemistry, 
and urinalysis). In addition, 12-lead electrocardiograms 
(ECGs) and 24-hour Holter monitoring were conducted 
during the study. Vital signs and 12-lead ECGs were 
measured at 15 and 45   minutes, 2, 4, 8, and 24 hours 
postdose on Day 1 and 7 of each treatment period. Lead 
II ECG monitoring was performed for 6 hours postdose 
at each treatment visit.
Pharmacokinetic assessments
Blood samples were collected to determine plasma 
concentrations of GSK233705 and salmeterol predose, 
5, 15, and 30 minutes, and 1 hour and 2 hours postdose 
on Day 1. On Day 7, samples were collected as for Day 1 
plus additional samples at 4 and 12 hours. Plasma samples 
were analyzed for GSK233705 and salmeterol using a 
validated analytical method based on protein precipitation, 
  followed by high-performance liquid chromatography with 
mass spectrometry. The lower limit of quantification was 
0.01 ng/mL for GSK233705 and 0.025 ng/mL for salmeterol. 
Urine samples were also analyzed for GSK233705 using 
a validated analytical method based on dilution followed 
by high-performance liquid chromatography with mass 
  spectrometry analysis.
Statistical analysis
The sample size was based on estimates of precision of the 
anticipated treatment differences in FEV1, rather than formal 
powering, since this was a preliminary hypothesis-generating 
study. Three analysis populations were used. The modified 
per protocol (MPP) population, which comprised all subjects 
who completed at least one posttreatment lung-function 
assessment in at least two treatment periods and in which 
major deviations from the protocol did not occur, was used to 
analyze efficacy. The safety population included all subjects 
who were randomized and had received at least one dose of 
study medication and was used for all safety summaries and 
analyses, background, and demography summaries. Analyses 
of vital signs and 12-lead ECG data included all subjects in 
the safety population who recorded a posttreatment value for 
the relevant parameter in at least two treatment periods. The 
pharmacokinetic (PK) concentration population comprised 
all subjects in the safety population for whom a PK sample 
was obtained and analyzed.
The primary comparison for which treatment differences 
were estimated was of each dose of GSK233705 plus 
salmeterol versus placebo. Secondary comparisons for which 
treatment differences were estimated were for each dose 
of GSK233705 plus salmeterol versus salmeterol alone or 
tiotropium. Trough FEV1 values on Day 2 and Day 8 were 
analyzed using a mixed effects analysis of covariance with 
period, baseline FEV1 by day, treatment by day, and mean 
baseline FEV1 by day fitted as fixed effects and subject 
as a random coefficient; adjusted means and treatment 
differences were calculated along with corresponding 95% 
confidence intervals (CIs). Trough FEV1 on Day 2 and trough 
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FVC endpoints were analyzed similarly. Prior to analysis, 
plethysmography parameters (sGaw, Raw, IC, and RV) were 
loge-transformed; the transformed parameters were analyzed 
in the same way as the primary efficacy parameter and back 
transformed prior to reporting. No formal statistical analysis 
was performed on safety data except for the maximum, 
minimum, and weighted mean parameters for 12-lead ECG 
QTc  Fridericia’s formula (F) and QTc Bazzett’s formula (B) 
and supine vital signs data, which were analyzed in the same 
way as the primary efficacy parameter.
The PK parameters were calculated by standard non-
compartmental analysis using WinNonlin® Pro (Pharsight, 
St Louis, MO). Plasma concentration data were listed and 
summarized (in tabular form as well as mean, median, and 
individual subject plots on the semilogarithmic and linear 
scales).
Results
Study population
A total of 47 dually responsive subjects were randomized, 
received treatment, and comprised the safety population. 
Four subjects (8.5%) were excluded from the MPP popula-
tion due to failing to complete a baseline and posttreatment 
assessment for at least one efficacy parameter in at least 
two periods.
In  the  MPP  population,  23  subjects  received 
GSK233705 20 µg + salmeterol, 27 received GSK233705 
50 µg +   salmeterol, 27 received salmeterol alone, 28 received 
tiotropium alone, and 24 received placebo. The mean % pre-
dicted postbronchodilator FEV1 was 55% at screening and the 
mean percent reversibilities to ipratropium and salbutamol 
were 26% and 23%, respectively. The demographic and 
baseline characteristics of the safety and MPP study popula-
tions are shown in Table 1.
Efficacy
Primary endpoint
Trough FEV1 on Day 8
Raw mean trough FEV1 on Day 8 was higher for all 
active treatments than for placebo (Figure 1). All active 
treatments increased trough FEV1 on Day 8 by more than 
120 mL compared with baseline, whereas the increase 
after placebo treatment was only 20 mL (adjusted mean 
differences).
Compared with placebo, the increase in trough FEV1 
was 215 mL higher with GSK233705 20 µg + salmeterol 
and 203 mL higher with GSK233705 50 µg + salmeterol, 
Table 1 Baseline demographics and characteristics of the safety 
and modified per protocol (MPP) populations
Safety population 
(N = 47)
MPP population 
(N = 43)
Age (years)
  Mean (SD) 
  Range
 
62.6 (6.9) 
47–75
 
62.3 (7.1) 
47–75
Gender, n (%) 
  Female 
  Male
 
18 (38%) 
29 (62%)
 
18 (42%) 
25 (58%)
Ethnicity, n (%) 
  White
 
47 (100%)
 
43 (100%)
Body mass index (kg/m2) 
  Mean (SD) 
  Range
 
25.3 (2.9) 
20.2–30.9
 
25.3 (3.0) 
20.2–30.9
Smoking history 
  Current/former n (%)
 
23 (49%)/24 (51%)
 
21 (49%)/22 (51%)
Years smoked 
  Mean (SD) 
  Range
 
38.8 (8.9) 
20–60
 
38.6 (9.0) 
20–60
Number of cigarettes/day 
  Mean (SD) 
  Range
 
20.5 (7.8) 
5–40
 
20.7 (7.8) 
5–40
Smoking pack years 
  Mean (SD) 
  Range
 
40.0 (19.2) 
11.5–90.0
 
40.3 (19.4) 
11.5–90.0
Postbronchodilator  
FEV1 at screening 
% predicted normal FEV1 
  Mean (SD) 
  Range 
% reversibility in baseline  
FEV1 ipratropium 
  Mean (SD) 
  Range 
Salbutamol 
  Mean (SD) 
  Range
 
 
 
55.3 (10.5) 
39.8–84.9 
 
 
26.3 (11.3) 
9.3–52.4 
 
24.6 (11.5) 
10.6–66.7
 
 
 
54.8 (9.5) 
39.8–72.1 
 
 
25.7 (10.7) 
9.3–52.4 
 
23.3 (9.4) 
10.6–52.7
COPD medication  
during treatment 
  N (%)
 
 
37 (79%)
 
 
34 (79%)
Inhaled corticosteroids  
during treatment 
  N (%)
 
 
25 (53%)
 
 
23 (53%)
Abbreviations: FEV1 , forced expiratory volume in 1 second; SD, standard deviation.
whereas with salmeterol and tiotropium alone the increases 
were 101 mL and 118 mL higher, respectively. Larger 
increases from baseline in trough FEV1 on Day 8 were also 
seen with the combination treatments compared with the indi-
vidual treatments (Table 2). For all treatment comparisons 
performed, the lower 95% CI for the treatment difference 
was .0, giving strong statistical evidence of a benefit of 
the combination treatments over placebo, salmeterol, and 
tiotropium, and of salmeterol and tiotropium over placebo 
(Table 2).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
156
Beier et alInternational Journal of COPD 2012:7
Secondary endpoints
Trough FEV1 on Day 2
Raw mean trough FEV1 on Day 2 was higher for all active 
treatments than for placebo (Figure 2), and all treatments 
increased trough FEV1 on Day 2 compared with baseline. 
Compared with placebo, the increase from baseline 
in trough FEV1 was 306 mL higher with GSK233705 
20 µg + salmeterol and 251 mL higher with GSK233705 
50 µg + salmeterol, whereas with salmeterol and tiotropium 
the increases were 105 mL and 136 mL higher, respectively. 
Larger increases from baseline in trough FEV1 on Day 2 were 
also seen with the combination treatments compared with the 
individual treatments: 201 mL versus salmeterol and 170 mL 
versus tiotropium for GSK233705 20 µg + salmeterol and 
145 mL versus salmeterol and 115 mL versus tiotropium for 
GSK233705 50 µg + salmeterol.
For all treatment comparisons performed, the lower 
95% CI for the treatment difference was .0, giving strong 
  statistical evidence of a benefit of the combination treatments 
over placebo, salmeterol, and tiotropium, and of salmeterol 
and tiotropium over placebo (Table 3).
Trough FVC and postdose FVC
Trough FVC and postdose FVC values followed a similar 
pattern to that observed for the FEV1 endpoints. Compared 
with placebo, the change from baseline in trough FVC on Day 
8 was 411 mL higher with GSK233705 20 µg + salmeterol 
and 355 mL higher with GSK233705 50 µg + salmeterol, 
whereas with salmeterol and tiotropium the changes were 
144 mL and 257 mL higher, respectively. Trough FVC values 
and treatment differences on Day 2 were generally higher 
than those recorded on Day 8. For all comparisons of com-
bination treatments and tiotropium with placebo, the lower 
95% CI for the treatment difference was .0, giving strong 
statistical evidence of a benefit. The evidence was less strong 
for the benefit of salmeterol over placebo. Correspondingly 
there was statistical evidence (lower 95% CI . 0) of a benefit 
of combination treatment over salmeterol, but no consistent 
statistical evidence of a benefit over tiotropium.
All active treatments increased postdose serial FEV1, 
and postdose FVC relative to placebo at all time points 
on both days, with the combination treatments again 
showing an improvement compared with salmeterol alone 
and tiotropium alone (Figure 3). For all comparisons of 
combination treatments with placebo, the lower 95% CI for 
the ratio between treatments was .0, giving strong statistical 
evidence of a benefit.
Plethysmography
All active treatments increased trough sGaw on Day 8 by 
more than 22% compared with baseline, whereas placebo 
treatment showed a 3% decrease from baseline. The ratio 
to baseline compared with placebo was 49.8% higher with 
GSK233705 20 µg + salmeterol and 65.9% higher with 
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Figure  1  Box  plot  of  raw  mean  trough  (morning,  predose)  forced  expiratory 
volume in 1 second (FEV1) on Day 8 (modified per protocol population). 
Abbreviations: SAL, salmeterol; TIO, tiotropium.
Table 2 Analysis of trough (morning, predose) forced expiratory volume in 1 second (L) on Day 8 (modified per protocol population)
GSK233705 20 μg +  
salmeterol
GSK233705 50 μg +  
salmeterol
Salmeterol Tiotropium Placebo
n 22 26 27 28 24
Baseline raw mean (SD) 1.16 (0.31) 1.29 (0.43) 1.29 (0.42) 1.20 (0.34) 1.19 (0.36)
Endpoint adjusted mean (SE) 1.46 (0.03) 1.45 (0.03) 1.35 (0.03) 1.37 (0.03) 1.25 (0.03)
Adjusted mean change from baseline (SE) 0.24 (0.03) 0.22 (0.03) 0.12 (0.03) 0.14 (0.03) 0.02 (0.03)
Difference from placebo (SE) 
95% CI
0.21 (0.04) 
(0.14, 0.29)
0.20 (0.03) 
(0.13, 0.27)
0.10 (0.03) 
(0.03, 0.17)
0.12 (0.03) 
(0.05, 0.18)
Difference from salmeterol (SE) 
95% CI
0.11 (0.03) 
(0.04, 0.18)
0.10 (0.03) 
(0.04, 0.17)
Difference from tiotropium (SE) 
95% CI
0.10 (0.03) 
(0.03, 0.17)
0.08 (0.03) 
(0.02, 0.15)
Abbreviations: CI, confidence interval; SD, standard deviation; SE, standard error of the mean.
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GSK233705 50 µg + salmeterol, whereas with salmeterol 
and tiotropium bromide the ratios were 26.6% and 29.8% 
higher, respectively.
Postdose sGaw, trough Raw, and postdose Raw also 
reflected the spirometric results (as did IC and RV to a lesser 
extent) (Table 4).
Morning PEF
The combination treatments both increased PEF by approxi-
mately 35 L/min compared with placebo whereas salmeterol 
and tiotropium increased PEF by 20 L/min and 15 L/min, 
respectively. For all treatment comparisons performed, the 
lower 95% CI for the treatment difference was .0, indicating 
strong statistical evidence of a benefit of the combination 
treatments over placebo, salmeterol and tiotropium, and of 
salmeterol and tiotropium over placebo.
Rescue use
For subjects receiving GSK233705 20 µg + salmeterol and 
GSK233705 50 µg + salmeterol, 52.4%, and 46.2% never 
needed to use their salbutamol rescue medication during the 
treatment period, compared with 44.4% of subjects receiving 
salmeterol, 32.1% of subjects receiving tiotropium, and 
16.7% of subjects receiving placebo.
Safety
AEs
The safety profiles were similar across all treatments. The most 
common AEs with onset while on-treatment were headache 
and ventricular extrasystoles (Table 5). Headache was the most 
frequently reported treatment-related AE and was reported 
by one subject on each of GSK233705 20 µg + salmeterol, 
tiotropium, and placebo. No serious AEs were reported in 
treated subjects. Four subjects were withdrawn; three due to an 
exacerbation (two following treatment with placebo and one 
after salmeterol) and one subject on salmeterol treatment had 
an AE of nonsustained ventricular tachycardia (,30 beats), 
which led to withdrawal from the study.
Vital signs
The changes in heart rate from baseline on Day 1 and Day 7 
were similar for all treatments including placebo. There was 
some evidence of a small increase in heart rate on salmeterol 
compared with placebo on Day 1, with lower CIs above zero 
for the comparisons of both weighted mean and maximum 
heart rate over 0–24 hours. Similar evidence was seen for a 
decrease in heart rate on the combination treatments compared 
with salmeterol, with upper CIs , 0 for the comparison of 
each combination treatment with salmeterol for weighted 
mean and minimum heart rate, and for the comparison of 
GSK233705 50 µg + salmeterol with salmeterol for maximum 
heart rate. These differences were small, with maximum and 
minimum 95% CIs less than ±6.4 bpm. However, similar 
evidence was not seen on Day 7.
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Figure  2  Box  plot  of  raw  mean  trough  (morning,  predose)  forced  expiratory 
volume in 1 second (FEV1) on Day 2 (modified per protocol population). 
Abbreviations: SAL, salmeterol; TIO, tiotropium.
Table 3 Analysis of trough (morning, predose) forced expiratory volume in 1 second (L) on Day 2 (modified per protocol population)
GSK233705 20 μg + 
salmeterol
GSK233705 50 μg + 
salmeterol
Salmeterol Tiotropium Placebo
n 23 27 27 28 24
Baseline raw mean (SD) 1.18 (0.32) 1.29 (0.42) 1.29 (0.42) 1.20 (0.34) 1.19 (0.36)
Endpoint adjusted mean (SE) 1.55 (0.03) 1.49 (0.03) 1.34 (0.03) 1.37 (0.03) 1.24 (0.03)
Adjusted mean change from baseline (SE) 0.32 (0.03) 0.23 (0.028) 0.12 (0.03) 0.15 (0.03) 0.01 (0.03)
Difference from placebo (SE) 
95% CI
0.31 (0.04) 
(0.23, 0.38)
0.25 (0.04) 
(0.17, 0.33)
0.10 (0.04) 
(0.03, 0.18)
0.14 (0.037) 
(0.06, 0.21)
Difference from salmeterol (SE) 
95% CI
0.20 (0.04) 
(0.12, 0.28)
0.14 (0.04) 
(0.07, 0.22)
Difference from tiotropium (SE) 
95% CI
0.17 (0.04) 
(0.09, 0.25)
0.11 (0.04) 
(0.04, 0.19)
Abbreviations: CI, confidence interval; SD, standard deviation; SE, standard error of the mean.
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Figure 3 Adjusted mean (95% confidence interval) forced expiratory volume in 1 second (FEV1) over time on Day 7 (modified per protocol population). 
Abbreviations: SAL, salmeterol; TIO, tiotropium.
Table 4 Trough sGaw, Raw, IC, and RV on Day 2 and Day 8 (modified per protocol population)
GSK233705  
20 μg + salmeterol
GSK233705  
50 μg + salmeterol
Salmeterol Tiotropium Placebo
Day 2
n 23 27 27 27 24
Trough sGaw 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
0.79 
1.68 (1.48, 1.91)
 
0.84 
1.77 (1.57, 2.00)
 
0.56 
1.19 (1.05, 1.35)
 
0.59 
1.26 (1.11, 1.42)
 
0.47
Trough Raw 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
0.26 
0.62 (0.54, 0.70)
 
0.25 
0.60 (0.53, 0.67)
 
0.36 
0.86 (0.76, 0.97)
 
0.33 
0.80 (0.71, 0.90)
 
0.42
Trough IC 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
2.25 
1.13 (1.06, 1.21)
 
2.17 
1.09 (1.03, 1.16)
 
2.01 
1.02 (0.96, 1.08)
 
2.09 
1.06 (0.99, 1.12)
 
1.98
Trough RV 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
3.02 
0.85 (0.78, 0.92)
 
3.06 
0.857 (0.79, 0.93)
 
3.31 
0.93 (0.85, 1.01)
 
3.32 
0.932 (0.86, 1.01)
 
3.57
Day 8
n 21 26 27 28 24
Trough sGaw 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
0.66 
1.50 (1.31, 1.70)
 
0.73 
1.66 (1.47, 1.87)
 
0.56 
1.27 (1.12, 1.43)
 
0.57 
1.30 (1.15, 1.47)
 
0.44
Trough Raw 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
0.31 
0.71 (0.62, 0.81)
 
0.29 
0.65 (0.58, 0.74)
 
0.36 
0.81 (0.72, 0.92)
 
0.35 
0.80 (0.71, 0.91)
 
0.44
Trough IC 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
2.16 
1.12 (1.04, 1.20)
 
2.17 
1.12 (1.05, 1.20)
 
2.03 
1.05 (0.98, 1.12)
 
2.07 
1.07 (1.00, 1.14)
 
1.93
Trough RV 
  Endpoint adjusted geometric mean 
  Ratio of individual treatments to placebo (95% CI)
 
3.03 
0.84 (0.79, 0.90)
 
3.03 
0.84 (0.79, 0.90)
 
3.33 
0.93 (0.87, 0.98)
 
3.31 
0.92 (0.87, 0.98)
 
3.59
Abbreviations: CI, confidence interval; IC, inspiratory capacity; Raw, airways resistance; RV, residual volume; sGaw, plethysmography parameters airway conductance.
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The changes in systolic and diastolic blood pressure 
from baseline on Day 1 and Day 7 were similar between 
all   treatments including placebo. Treatment differences 
for weighted mean, maximum and minimum systolic and 
  diastolic blood pressure over 0–4 hours and 0–24 hours were 
small, and in all cases except one the CIs for all treatment 
comparisons contained zero.
ECGs
No clinically significant changes in ECG traces during any 
visit postbaseline were reported for any treatment. Summary 
statistics for Holter ECG parameters (maximum, mean and 
minimum heart rate, maximum and mean uncorrected QT, 
maximum RR, mean QTc(B) and QTc(F), number of RR 
intervals .2 msec, and number of ventricular couplets, 
triplets and nonsustained ventricular tachycardias, and 
supraventricular tachycardias) were similar for all treatments 
at screening and on Day 1 and Day 7.
Pharmacokinetics
The bioanalytical method (LLQ of 0.01 ng/mL) for 
GSK233705 was not sensitive enough to fully characterize 
the PK profile of subjects due to the low level of GSK233705 
detected in plasma. Overall, 52% of data were nonquantifiable. 
Following single and repeat inhaled dose administration, 
GSK233705 was rapidly absorbed. The median tmax was 
5 minutes, irrespective of dose levels (20 µg and 50 µg) and 
sampling days (Day 1 and Day 7). Plasma concentrations 
declined rapidly following the occurrence of Cmax. Plasma 
concentrations following repeat inhaled administration were 
on average higher than those after single dosing for both 
dose levels suggestive of accumulation. Moderate to high 
between-subject variability in Cmax was observed with values 
of the coefficient of variation ranging from 42% to 60% on 
Day 1, and from 42% to 52% on Day 7 across dose levels. 
Moderate to high between-subject variability in AUC(0–t) 
was also observed with values of the coefficient of variation 
ranging from 29% to 67% on Day 1, and from 98% to 130% 
on Day 7 across dose levels (Table 6).
The bioanalytical method (LLQ of 0.025 ng/mL) for 
salmeterol was not sensitive enough to fully characterize 
the PK profile of subjects due to the low level of salmeterol 
detected in plasma. For salmeterol, overall 55% (604/1092) 
of data was nonquantifiable. The median tmax was 30 minutes 
or less irrespective of sampling day or whether salmeterol 
was administered alone or in combination with GSK233705. 
Moderate between-subject variability in Cmax was observed 
with values of the coefficient of variation ranging from 29% 
to 38% on Day 1, and from 41% to 53% on Day 7 across treat-
ment regimens. Moderate to high between-subject variability 
in AUC(0–t) was also observed with values of the coefficient 
of variation ranging from 35% to 54% on Day 1, and from 
68% to 124% on Day 7 across treatment regimens.
Discussion
The objectives of this pilot study were to investigate the 
bronchodilatory efficacy, safety, and tolerability of twice-daily 
therapy with two different long-acting bronchodilators in a 
COPD population optimized to demonstrate a response. These 
were administered concurrently (GSK233705 + salmeterol) 
and compared primarily with placebo but also compared with 
twice-daily salmeterol monotherapy or once-daily tiotropium 
monotherapy in subjects with moderate to severe COPD. 
The primary lung function measurements were made using 
spirometry, and this was supported by plethysmography, 
which provides a further sensitive assessment of lung 
Table 5 Adverse events (AEs) with onset on-treatment experienced by more than one subject on any treatment (safety population)
AE n (%) GSK233705 20 μg + 
salmeterol (N = 23)
GSK233705 50 μg + 
salmeterol (N = 27)
Salmeterol 
(N = 29)
Tiotropium 
(N = 28)
Placebo 
(N = 26)
Subjects with any AE 14 (61%) 11 (41%) 16 (55%) 16 (57%) 12 (46%)
Nasopharyngitis 
Urinary tract infection 
Influenza
1 (4%) 
1 (4%) 
2 (9%)
0 
0 
0
1 (3%) 
1 (3%) 
0
1 (4%) 
1 (4%) 
2 (7%)
2 (8%) 
2 (8%) 
0
headache 
Dizziness
4 (17%) 
1 (4%)
2 (7%) 
2 (7%)
2 (7%) 
0
5 (18%) 
1 (4%)
3 (11%) 
0
Ventricular extrasystoles 
Ventricular tachycardia 
Supraventricular tachycardia 
Supraventricular extrasystoles
1 (4%) 
1 (4%) 
1 (4%) 
0
1 (4%) 
0 
0 
0
3 (10%) 
2 (7%) 
0 
2 (7%)
1 (4%) 
1 (4%) 
2 (7%) 
0
0 
0 
0 
0
Back pain 0 0 2 (7%) 0 3 (11%)
Leukocyturia 0 2 (7%) 0 1 (4%) 0
Fatigue 0 0 0 1 (4%) 2 (8%)
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function16 and also takes into account effects on both the 
large and small airways.
A crossover design was chosen because the within-patient 
variability in FEV1 was expected to be less than between-
patient variability, with each patient acting as their own 
control. An incomplete-block, rather than a complete-block, 
crossover design was adopted (with three periods) to reduce 
the study duration and overall burden on patients. To fully 
blind the study, each subject would have needed to use both 
inhalers on a double-dummy basis and to take multiple 
inhalations morning and evening. In order to reduce the 
number of inhalers subjects needed to take daily, the study 
was blinded for active versus placebo treatments but not with 
respect to inhaler type. The duration of 2 weeks for washout 
was also sufficient to minimize the possibility of carry-over 
effects of both salmeterol and tiotropium. It is recognized 
however that a limitation of the study was that there was no 
GSK233705 monotherapy arm.
Concurrent use of GSK233705 at doses of 20 µg or 50 µg 
twice-daily plus salmeterol 50 µg twice-daily for 7 days 
resulted in clinically important improvements in lung function 
which were greater than those seen with placebo, salmeterol 
50 µg twice-daily alone, or tiotropium 18 µg once-daily 
alone. The improvement versus placebo in bronchodilation 
with both doses of GSK233705 plus salmeterol was not only 
higher than the 100 mL criterion described by Donohue17 as 
a difference that COPD patients can perceive but also was 
well above the range (100–140 mL) proposed as a minimal 
clinically important difference.18
The clinical improvements seen in lung function were 
also supported by the results of daily diary card assessments, 
morning PEF measurements, and rescue medication use, all 
of which suggested that dual bronchodilator treatment has the 
potential to produce a clinically important additional benefit 
on symptoms compared with a single agent. It has previously 
been shown that these two classes of bronchodilator added 
together result in a significant reduction in salbutamol use 
as rescue therapy and symptoms of dyspnoea.5,19 This study 
provides further support for these observations. Although 
this study did not include symptom assessments, the need 
for rescue medication is a useful surrogate of symptomatic 
benefit and reductions in the use of rescue medication were 
seen with the combination treatments compared with each 
of the individual treatments.
The positive primary efficacy results were supported by the 
results from all of the remaining lung function assessments.
Although this was a small study, and the endpoints 
not formally powered, the results were consistent across 
virtually every endpoint studied and the sizes of the treatment 
differences were compelling. No obvious dose response was 
observed between the two doses of GSK233705 in combina-
tion with salmeterol for any of the endpoints, but the study 
was not designed to differentiate between doses.
The safety findings from this study demonstrated that 
the safety profiles were similar across all treatments. No 
clinically significant effects on heart rate were observed 
with concurrent administration of GSK233705 and sal-
meterol and, importantly, analysis of 24-hour Holter ECG 
measurements did not identify any change in the incidence 
of the minor rhythm abnormalities frequently observed in 
COPD patients.
The pharmacokinetic information obtained in this study 
was limited due to a large amount of nonquantifiable data. 
However, the results showed that, following single and repeat 
inhaled doses, there was rapid absorption of both GSK233705 
and salmeterol with a median time to Cmax (tmax) of 5 minutes 
for GSK233705 and 30 minutes for salmeterol. The PK 
parameters for salmeterol were similar in the presence and 
absence of GSK233705, demonstrating an absence of any 
PK interaction between the two drugs.
Results from this study support previous findings which 
have demonstrated that a long-acting β-agonist added to a 
long-acting anticholinergic (tiotropium bromide) produce 
incremental effects on lung function. Data from both short-
term4–6,16 and long-term studies provide additional evidence 
that combining LAMAs and LABAs helps to maximize 
bronchodilation and improve symptoms and quality of life in 
patients with moderate to severe disease.7–8,20 Importantly, in 
this study no increase in the risk of side effects was observed 
with the combinations compared with monotherapies.
Most subjects recruited for this study had moderate 
disease and were documented to demonstrate significant 
bronchodilator responses to both anticholinergics and 
β2-agonists. This further supports the use of LABA/LAMA 
combination therapy in moderate COPD if maintenance 
treatment with a single long-acting bronchodilator does not 
suffice.1–3 Published evidence to date also supports the use 
of a combination therapy with tiotropium plus a LABA even 
in those COPD patients with more severe symptoms.8,21,22 
However, limited analyses have been performed to date to 
assess the differential effects of LAMA therapy by severity 
of COPD. Clinical studies have included patients with disease 
severity ranging from moderate to very severe disease. 
Tashkin et al6 found that while improvements in lung function 
were greater in more severe COPD, dyspnea scores improved 
irrespective of severity.
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It has been hypothesized that activity of the sympathetic 
system is more prominent during the day, whereas increased 
parasympathetic system activity is found   during the night.21–25 
It therefore seems appropriate to target bronchoconstriction 
through two distinct mechanisms (anticholinergic and 
sympathomimetic) to maximize the bronchodilator 
response over 24 hours and help to overcome inter- and 
intra-patient variability in bronchomotor tone associated 
with COPD.26
A range of once and twice daily LAMAs are currently 
in clinical development as monotherapies in COPD.9,10 
A number of novel once-daily fixed-dose combination 
bronchodilators are also in phase III development, including 
QVA149 (a combination of indacaterol and NVA237)27 and 
vilanterol plus GSK573719.28
Conclusion
This study helps to demonstrate that combinations of 
these two classes of medications can achieve significant 
bronchodilation compared to monotherapy. The addition of 
GSK233705 to salmeterol resulted in greater bronchodilatation 
than salmeterol or tiotropium alone and was well tolerated. 
This particular bronchodilator combination is at present not 
being progressed further because once-daily alternatives are 
favored and being developed.
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